numer
preclin
studi
demonstr
efficaci
viral
gene
deliveri
vector
recent
clinic
trial
shown
promis
result
howev
tight
control
transgen
express
like
requir
therapeut
applic
instanc
safeti
reason
purpos
sever
liganddepend
transcript
regulatori
system
develop
among
tetracyclineregulat
system
far
frequent
use
advanc
toward
gene
therapi
trial
review
focu
system
describ
recent
progress
regul
transgen
express
variou
organ
includ
muscl
retina
brain
sinc
develop
immun
respons
transactiv
observ
follow
gene
transfer
muscl
nonhuman
primat
focu
therefor
given
immun
respons
transgen
product
tetracyclin
induc
promot
clinic
efficaci
safeti
well
applic
rang
gene
therapi
broaden
develop
system
capabl
fine
modul
express
therapeut
gene
regulat
system
turn
therapeut
gene
express
crucial
maintain
appropri
level
gene
product
within
therapeut
rang
thu
prevent
toxic
also
allow
turn
therapeut
gene
express
avoid
harm
side
effect
develop
liganddepend
transcript
regulatori
system
thu
great
import
use
human
gene
therapi
pharmacolog
regul
system
fulfil
sever
criteria
follow
ligand
activ
onswitch
rather
silenc
transcript
offswitch
offsystem
suffer
drawback
prolong
exposur
drug
requir
silenc
system
induct
kinet
mainli
determin
rate
drug
clearanc
induc
drug
oral
bioavail
penetr
target
tissu
system
interfer
endogen
metabol
pathway
induc
compound
drug
metabol
profil
compat
prolong
therapeut
use
transcript
fulli
rapidli
revers
enabl
prompt
chang
dose
regimen
system
inact
absenc
induc
drug
strongli
stimul
drug
administr
precis
correl
must
exist
drug
dosag
target
gene
express
level
transcript
activ
exhibit
low
potenti
elicit
immun
respons
human
four
drugdepend
regulat
system
meet
criteria
list
develop
vivo
control
transgen
express
tetracyclin
tet
rapamycin
regulat
system
mammalian
steroid
receptor
mifepriston
tamoxifen
insect
steroid
receptor
ecdysteroid
base
system
molecular
mechan
underli
regulatori
effect
pharmacolog
characterist
induc
drug
distinct
differ
regulatori
system
transgen
regul
document
vitro
rodent
model
review
tetracyclin
rapamycin
regulat
system
test
larg
anim
model
far
review
focu
tetracyclineregulat
system
besid
molecular
mechan
differ
variant
system
pharmacolog
characterist
induc
drug
regul
transgen
express
variou
organ
includ
muscl
retina
brain
explor
review
preclin
studi
potenti
relev
clinic
futur
gene
therapi
clinic
trial
discuss
detail
tetregulat
system
base
e
coli
tet
resist
operon
consist
tet
repressor
protein
tetr
tet
oper
dna
sequenc
teto
dna
absenc
tet
deriv
doxycyclin
dox
tetr
protein
get
attach
teto
dna
sequenc
presenc
drug
tetr
chang
conform
detach
dna
five
differ
tetrespons
regulatori
system
develop
base
bacteri
operon
system
normal
clone
two
differ
express
cassett
fig
first
two
system
contain
tetr
protein
fuse
transactiv
herp
simplex
viru
hsv
transgen
express
allow
absenc
dox
system
call
tetoff
wherea
transgen
express
allow
presenc
dox
system
call
teton
fig
third
system
contain
tetr
protein
fuse
transinhibitor
protein
box
krab
zink
finger
protein
tetrkrab
system
design
allow
transgen
express
presenc
dox
teton
fig
attempt
minim
background
level
transgen
express
two
altern
system
develop
first
one
combin
tetrkrab
system
combin
teton
fig
second
system
base
autoregulatori
loop
transactiv
constitut
express
control
induc
promot
autoregulatori
loop
fig
thu
make
possibl
one
express
cassett
intern
ribosom
entri
site
ire
bidirect
promot
section
system
go
describ
molecular
basi
better
understand
differ
vivo
applic
system
chimer
protein
product
dna
bind
domain
tetr
transactiv
domain
call
tta
tetcontrol
transcript
activ
seven
repeat
teto
dna
sequenc
also
refer
tre
tetrespons
element
fuse
upstream
minim
cmv
promot
p
min
cmv
form
compound
promot
p
absenc
dox
tta
bind
tre
thu
activ
p
result
express
adjac
gene
fig
dox
present
tta
chang
conform
detach
tre
gene
express
silenc
furth
colleagu
shown
first
time
function
system
vivo
bigen
mice
harbour
tta
gene
report
gene
minim
possibl
interact
transactiv
cellular
promot
avoid
onset
immun
reaction
protein
reduc
three
minim
repeat
amino
acid
tetoff
system
use
gene
express
maintain
switchon
state
long
time
turn
system
continu
administr
dox
would
requir
activ
transgen
express
depend
mainli
clearanc
kinet
dox
reason
limit
use
system
potenti
human
applic
due
use
system
restrict
earli
experi
vivo
four
mutat
tetr
domain
transactiv
tta
shown
revers
behaviour
protein
interact
tre
respons
presenc
absenc
dox
rather
attach
tre
absenc
dox
mutant
revers
tet
repressor
protein
rtetr
stay
solubl
bind
tre
presenc
dox
rtetr
fuse
domain
result
transactiv
protein
call
rtta
system
chang
teton
system
presenc
induc
drug
allow
express
transgen
fig
activ
transgen
express
found
rapid
compar
tetoff
system
howev
induc
transgen
express
use
teton
system
high
concentr
dox
requir
rais
question
whether
concentr
possibl
achiev
tissu
brain
urling
colleagu
studi
perform
sever
mutat
rtta
protein
develop
random
mutagenesi
codon
optimis
found
new
rtta
transactiv
particular
rtta
show
improv
sensit
induc
drug
reduc
background
activ
absenc
dox
system
confer
requir
use
human
patient
see
introduct
therefor
use
numer
vivo
studi
rodent
model
alreadi
advanc
preclin
studi
nonhuman
primat
due
fact
potenti
immun
respons
rtta
primarili
trigger
viral
part
fusion
protein
attempt
made
replac
part
rtta
less
immunogen
protein
deuschl
colleagu
develop
system
origin
tetr
protein
fuse
transrepress
domain
krab
human
zink
finger
protein
form
transinhibitor
call
tetrkrab
tt
studi
krab
domain
retriev
rodent
zink
finger
protein
transrepressor
call
tt
kid
zink
finger
protein
regulatori
protein
krab
domain
known
inhibit
rna
polymeras
ii
iii
within
rang
kb
dna
attach
site
second
part
tetrkrab
system
compound
promot
ptetocmvlg
use
express
transgen
consist
tre
fuse
upstream
normal
cmv
promot
need
activ
absenc
dox
tetrkrab
get
attach
tre
inhibit
activ
cmv
promot
presenc
dox
tetrkrab
get
detach
tre
thu
allow
transgen
express
fig
mechan
krab
inhibit
express
gene
entir
known
three
mechan
seem
involv
local
chang
chromatin
structur
trigger
heterochromatin
local
histon
deacetyl
indirect
influenc
arrang
gener
tetregulat
system
compos
two
distinct
express
cassett
one
contain
regulatori
protein
tta
rtta
tt
control
ubiquit
cell
type
specif
promot
cassett
second
cassett
contain
tetracyclin
respons
element
tre
fuse
promot
regul
express
report
therapeut
transgen
cassett
b
b
chimer
protein
tta
compos
tetr
fuse
viral
transactiv
absenc
dox
tta
protein
bind
tre
within
compound
promot
pcmv
min
allow
express
transgen
presenc
dox
tta
chang
conform
get
detach
tre
transgen
express
observ
c
rtta
transactiv
also
chimer
protein
compos
tetr
domain
howev
due
presenc
four
mutat
tetr
call
rtetr
domain
protein
fix
tre
presenc
dox
thu
allow
transgen
express
absenc
dox
rtta
get
detach
tre
transgen
express
observ
chimer
protein
tt
compos
tetr
fuse
krab
box
zink
finger
protein
absenc
dox
tt
bind
tre
inhibit
transgen
express
driven
normal
promot
ie
cmv
presenc
dox
tt
get
detach
tre
thu
allow
transgen
express
e
combin
teton
system
contain
rtta
tt
protein
simultan
express
cassett
absenc
dox
tt
protein
bind
minim
compound
promot
inhibit
even
low
background
express
rtta
protein
stay
detach
tre
presenc
dox
rtta
bind
tre
activ
express
transgen
tt
stay
detach
f
autoregulatori
loop
system
rtta
tta
transgen
interest
driven
compound
minim
promot
separ
intern
ribosom
entri
site
ire
absenc
dox
transgen
express
presenc
dox
transgen
transactiv
gene
interest
express
onset
express
take
longer
initi
suffici
amount
rtta
need
produc
complet
activ
system
basal
transcript
machineri
propos
integr
promot
inhibit
tetrkrab
system
howev
differ
studi
demonstr
effici
regul
transgen
express
vivo
use
nonintegr
adenovir
vector
system
use
transform
cell
line
vitro
vivo
differ
organ
mice
use
lentivir
vector
integr
viral
dna
minim
background
express
teton
system
krabmedi
inhibit
incorpor
addit
rtta
system
purpos
tt
gene
clone
bicistron
express
cassett
downstream
transactiv
separ
use
intern
ribosom
entri
site
ire
absenc
dox
rtta
would
stay
detach
tre
tt
would
fix
inhibit
background
express
transgen
presenc
dox
two
chimer
protein
would
chang
conform
revers
activ
thu
allow
transgen
express
fig
combin
system
use
sever
vivo
studi
low
background
activ
describ
maximum
level
transgen
express
presenc
dox
similar
pure
teton
system
howev
one
group
observ
progress
loss
transgen
express
cho
cell
transduc
lentivir
vector
contain
combin
system
longterm
cultur
repeat
induct
question
whether
express
three
foreign
protein
one
cell
neg
effect
immunolog
situat
vivo
address
addit
due
size
restrict
system
incorpor
singl
vector
system
use
avail
viral
vector
ie
aav
vector
may
caus
problem
observ
certain
protocol
system
use
vivo
sever
organ
includ
muscl
retina
brain
review
section
second
strategi
minim
background
express
place
transgen
transactiv
gene
interest
compound
tetinduc
promot
p
fig
use
system
rtta
express
absenc
induc
drug
contrast
origin
teton
system
rtta
express
place
constitut
promot
therefor
induc
p
promot
interact
constitut
express
rtta
doxindepend
nonspecif
manner
doxmedi
induct
express
gene
interest
may
take
longer
rtta
express
first
immunogen
potenti
toxic
transactiv
restrict
time
induct
evid
autoregulatori
loop
also
use
tetoff
mechan
place
tta
rather
rtta
transactiv
control
minim
cmv
promot
autoregulatori
loop
system
use
nake
plasmid
clone
lentivir
vector
vitro
sever
studi
vivo
discuss
section
dox
analogu
tet
welldocu
antibiot
drug
use
clinic
year
avail
oral
intraven
applic
bioavail
dox
oral
administr
compar
intraven
administr
almost
serum
halflif
calcul
tissu
penetr
excel
includ
brain
concentr
highest
liver
kidney
digest
tract
elimin
primarili
via
urin
faec
review
dox
current
consid
one
treatment
option
infecti
diseas
lyme
diseas
malaria
multiresist
staphylococcu
aureu
mrsa
infect
interestingli
dox
approv
fda
usag
treatment
rosacea
acn
subantimicrobi
dose
socal
antiinflammatorydos
dox
mgday
per
adult
person
correspond
less
mgkg
bodi
weight
side
effect
prolong
administr
dox
includ
renal
toxic
dosedepend
photosensit
dox
may
accumul
bone
young
patient
teeth
lead
teeth
decolour
decreas
bone
growth
rate
howev
main
concern
use
antibioticdriven
regulatori
switch
remain
possibl
rais
resist
antibiot
even
though
dox
dose
mgday
antiinflammatorydos
dox
less
consid
lead
develop
antibioticresist
organ
problem
potenti
rais
antibiot
resist
dox
may
also
overcom
use
hepat
metabolit
dox
lack
antibiot
activ
mice
condit
knockout
mice
effect
dox
switch
transgen
express
section
aim
review
use
tetregulat
system
regul
transgen
express
vivo
tabl
regard
organ
focu
given
advanc
strategi
term
potenti
clinic
applic
strategi
alreadi
reach
level
nonhuman
primat
last
stage
clinic
use
human
patient
tabl
highlight
gray
strategi
develop
regul
transgen
express
employ
teton
system
aavmedi
gene
transfer
either
muscl
chapter
retina
chapter
follow
high
capac
hc
adenovir
vectormedi
gene
transfer
liver
chapter
contrast
regul
transgen
express
brain
studi
predominantli
rat
often
rat
model
cn
diseas
focu
given
three
differ
strategi
teton
system
follow
lentivir
vectormedi
gene
transfer
ii
autoregulatori
loop
follow
aavmedi
gene
transfer
iii
combin
teton
system
follow
hcad
vectormedi
gene
transfer
organ
cancer
model
publish
studi
limit
earli
experi
perform
mice
therefor
mention
detail
follow
section
skelet
muscl
one
largest
organ
system
mammalian
organ
easili
access
therefor
attempt
express
therapeut
protein
skelet
muscl
one
earliest
applic
regul
gene
therapi
due
facil
quantif
erythropoietin
epo
serum
obviou
biolog
effect
increas
hematocrit
level
induc
anim
hormon
use
mani
publish
work
report
gene
besid
epo
report
gene
use
studi
regul
transgen
express
muscl
ie
secret
alkalin
phosphatas
seap
luciferas
lu
addit
sever
studi
employ
potenti
therapeut
protein
exampl
proof
principl
experi
regul
transgen
express
use
tetoff
system
skelet
heart
muscl
mice
follow
direct
plasmid
inject
preclud
muscl
direct
gene
transfer
tetoff
regulatori
system
encapsid
aav
vector
soon
afterward
teton
system
also
use
control
epo
express
skelet
muscl
follow
cell
base
aavmedi
gene
transfer
bohl
colleagu
construct
aav
vector
origin
rtta
transactiv
place
control
strong
cmv
promot
murin
epo
express
cassett
construct
way
cassett
laid
directli
opposit
within
one
week
dox
administr
via
drink
water
epo
concentr
serum
rais
decreas
baselin
level
within
day
dox
withdraw
follow
induct
epo
express
hematocrit
level
increas
accordingli
demonstr
biolog
activ
transgen
epo
immun
respons
observ
mice
either
rtta
transactiv
epo
protein
similar
result
lead
tight
longterm
control
epo
express
observ
murin
model
encourag
result
mice
led
transfer
system
nonhuman
primat
muscl
favr
colleagu
inject
vector
carri
teton
rtta
transactiv
skelet
muscl
primat
initi
primat
show
tight
regul
transgen
express
rapid
induct
deinduct
kinet
follow
intraven
dox
administr
serum
epo
level
increas
maximum
within
day
follow
increas
reticulocyt
count
serum
demonstr
biolog
activ
transgen
epo
anim
regularli
bled
avoid
high
hematocrit
discomfort
follow
induct
howev
induc
epo
express
follow
intraven
inject
dox
vanish
complet
lost
follow
two
five
dox
puls
due
appear
humor
cellular
respons
transactiv
protein
result
destruct
rttaexpress
cell
within
skelet
muscl
detail
see
chapter
review
obtain
stringent
regul
transgen
express
optimis
version
transactiv
clone
differ
orient
express
cassett
incorpor
vector
transfer
muscl
mice
subsequ
nonhuman
primat
addit
woodchuck
hepat
posttranscript
regulatori
element
wpre
introduc
follow
epo
cdna
base
evalu
differ
design
express
cassett
mice
observ
promot
drive
express
transgen
posit
apart
orient
direct
forward
induc
optim
background
express
remain
minim
cassett
forward
studi
muscl
nonhuman
primat
use
serotyp
shown
use
serotyp
transduct
primat
skelet
muscl
almost
time
higher
serum
epo
concentr
could
observ
compar
anim
inject
serotyp
addit
induc
system
seem
effect
nonhuman
primat
mice
sinc
increas
serum
epo
could
observ
almost
baselin
activ
mice
differ
around
howev
valu
studi
caution
baselin
express
epo
could
quit
undetect
primat
due
larg
volum
blood
circulatori
system
would
dilut
serum
concentr
epo
teton
system
also
use
regul
transgen
express
follow
gene
transfer
adenovir
vector
antiangiogen
factor
mice
seap
primat
epo
express
also
studi
control
teton
system
follow
nake
dna
transfect
mice
importantli
studi
perform
lattamahieu
colleagu
primat
strong
cellular
humor
immun
respons
transactiv
led
loss
transgen
express
probabl
destruct
transgen
express
cell
agreement
result
obtain
studi
perform
favr
et
al
detail
see
chapter
review
interleukin
strong
antiinflammatori
cytokin
may
offer
potenti
treatment
option
rheumatoid
arthriti
ra
construct
intramuscular
inject
two
aav
vector
contain
gene
control
teton
regulatori
system
result
profound
express
transduc
muscl
mous
model
chronic
inflammatori
arthriti
durat
week
similar
strategi
propos
group
use
plasmid
transfect
strategi
express
control
combin
teton
system
tt
durat
month
combin
teton
system
also
employ
sever
studi
regul
epo
express
muscl
either
follow
aavmedi
gene
transfer
adenovir
vectormedi
gene
transfer
use
plasmid
transfect
one
studi
examin
control
express
differ
domain
antiangiogen
factor
plasminogen
follow
plasmid
gene
transfer
studi
perform
mice
demonstr
success
regul
transgen
express
addit
lamartina
colleagu
studi
regul
express
seap
skelet
muscl
primat
follow
direct
plasmid
inject
even
though
control
epo
express
mous
muscl
could
demonstr
year
studi
perform
primat
muscl
last
day
suffici
longterm
analysi
tetmedi
regul
autoregulatori
loop
construct
tetoff
system
also
use
studi
regul
express
epo
skelet
muscl
mice
encapsul
myoblast
transfect
plasmid
contain
autoregulatori
loop
tetoff
system
epo
report
gene
implant
epo
express
control
period
week
durat
experi
optimis
tetoff
express
cassett
report
aghamohammadi
et
al
studi
number
tet
oper
element
fuse
compound
minim
promot
increas
promot
sequenc
shorten
new
compon
tetregulat
system
incorpor
aav
vector
express
mous
granulocytemacrophag
coloni
stimul
factor
mgmgsf
control
period
week
follow
intramuscular
inject
recent
experi
transgen
regul
skelet
muscl
perform
lena
colleagu
studi
capac
combin
teton
ttskid
system
regul
epo
express
mice
follow
hcadmedi
gene
transfer
observ
develop
cellular
immun
respons
lead
loss
transgen
regul
within
week
gene
transfer
observ
reminisc
observ
primat
howev
use
lower
dose
adenovir
vector
employ
musclespecif
promot
suffici
avoid
immun
reaction
mice
led
sustain
regul
transgen
express
week
conclus
stringent
regul
transgen
express
muscl
possibl
use
tetregulat
system
howev
appear
strong
immun
respons
transactiv
regardless
origin
optimis
version
nonhuman
primat
make
difficult
advanc
system
issu
discuss
section
review
express
sever
neurotroph
factor
ciliari
neurotroph
factor
cntf
brain
deriv
neurotroph
factor
bdnf
retina
shown
delay
onset
retin
degener
varieti
anim
model
retin
pigmentosa
howev
longterm
exposur
retin
cell
cntf
decreas
electroretinogram
erg
respons
due
downregul
sever
transcript
factor
photoreceptor
therefor
regul
express
neurotroph
protein
retina
would
tabl
regul
transgen
express
tetracyclin
depend
system
vivo
gray
studi
involv
nonhuman
primat
avoid
onset
neg
side
effect
conserv
neuroprotect
activ
similar
strategi
current
develop
neovascular
disord
treatment
consist
current
inject
antivegf
molecul
repeatedli
vitreou
inhibit
vegfmedi
neovascularis
agerel
macula
degener
diabet
retinopathi
longterm
blockag
vegf
activ
express
antivegf
molecul
retina
may
deleteri
vegf
hold
also
neuroprotect
activ
neuron
respons
normal
develop
vasculatur
therefor
regul
transgen
express
would
import
step
toward
clinic
applic
first
ever
evalu
tetregulat
control
transgen
express
retina
mcgee
sanftner
et
al
use
dual
vector
system
two
vector
contain
either
combin
teton
ttskid
cassett
enhanc
gfp
gene
control
induc
minim
cmv
promot
mix
vector
inject
subretin
rat
thu
target
photoreceptor
retin
pigment
epithelium
rpe
result
demonstr
success
induct
deinduct
gfp
express
within
week
dox
administr
withdraw
respect
appar
side
effect
observ
howev
gfp
express
rel
low
compar
cmv
driven
express
due
ratio
vector
inject
gfp
contain
vector
combin
teton
contain
vector
well
necess
vector
transduc
cell
oral
administr
dox
low
level
allow
onset
gfp
express
increas
increas
dose
dox
administ
folliot
colleagu
use
singl
aav
vector
carri
tetoff
system
control
transgen
express
retina
recombin
vector
carri
destabilis
gene
control
tetoff
system
inject
intravitr
rat
warrant
transduct
retin
ganglion
cell
regul
express
tight
retin
gfp
signal
gone
within
h
follow
oral
administr
dox
via
drink
water
upon
dox
withdraw
reexpress
slower
return
full
signal
within
day
although
readili
detect
h
teton
system
use
regul
interleukin
express
intravitr
administr
rat
eye
mrna
could
detect
rtpcr
doxinduc
retina
two
week
drug
administr
control
noninduc
retina
mockinject
retina
remain
undetect
rtpcr
upon
induct
experiment
autoimmun
uveiti
anim
inject
induc
dox
show
partial
protect
photoreceptor
degener
due
presenc
transgen
noninduc
anim
mockinject
anim
develop
sever
uveiti
near
complet
loss
photoreceptor
group
develop
regulatori
system
base
teton
techniqu
control
express
epo
eye
nonhuman
primat
use
epo
report
protein
allow
easi
object
quantif
transgen
express
anterior
chamber
fluid
repres
advantag
subject
evalu
gfp
express
three
differ
vector
tetonepo
inject
total
seven
primat
induct
epo
express
perform
initi
dox
puls
given
intraven
mgkgday
day
postdox
administr
epo
concentr
reach
peak
declin
background
level
within
day
withdraw
induc
drug
maximum
epo
concentr
acf
muml
muml
muml
anim
inject
vector
respect
show
rang
two
order
magnitud
possibl
concentr
given
therapeut
protein
depend
serotyp
amount
vector
inject
promot
drive
express
protein
regul
transgen
express
still
observ
date
year
follow
administr
aav
teton
vector
fig
immun
respons
observ
either
transgen
product
rtta
epo
aav
vector
use
sinc
possibl
oral
administr
dox
key
consid
advanc
clinic
trial
also
evalu
influenc
oral
administr
capac
control
transgen
express
studi
demonstr
equal
effici
tight
control
induct
deinduct
epo
express
follow
oral
administr
dox
also
abl
show
system
capabl
continu
induc
transgen
express
time
period
month
without
elicit
neg
side
effect
therefor
follow
extens
preclin
experi
nonhuman
primat
model
consid
regulatori
system
use
tool
develop
neurotroph
antiangiogen
gene
therapi
strategi
retina
express
therapeut
gene
brain
follow
viral
vectormedi
gene
transfer
power
option
potenti
treatment
variou
neurolog
disord
includ
parkinson
diseas
huntington
diseas
hd
alzheim
diseas
brain
cancer
recent
advanc
identifi
key
obstacl
success
gene
therapi
applic
brain
ie
mode
deliveri
potenti
immun
respons
vector
transgen
rais
hope
clinic
trial
realiz
near
futur
howev
need
regul
transgen
express
remain
issu
treatment
brain
disord
last
decad
varieti
strategi
regul
express
transgen
brain
develop
employ
differ
version
tet
system
differ
report
gene
differ
viral
vector
model
organ
brain
direct
gene
transfer
use
regulatori
system
predominantli
rat
proof
principl
vivo
tet
regul
express
brain
perform
use
aav
vector
transfer
gfp
control
autoregulatori
loop
teton
system
respect
adenovir
vector
use
transfer
gfp
lu
tyrosin
hydroxylas
th
compar
teton
rtta
tetoff
tta
system
side
side
use
teton
rtta
system
tetoff
system
alon
addit
possibl
use
lentivir
vector
transfer
demonstr
use
tetoff
system
control
gfp
express
recent
even
vector
system
use
transfer
regulatori
system
brain
report
gene
lacz
driven
control
tetoff
system
jiang
colleagu
studi
effect
orient
two
express
cassett
tetoff
system
within
aav
vector
follow
intracerebr
gene
transfer
observ
best
control
transgen
express
minim
basal
leaki
construct
promot
drive
tta
gfp
express
posit
end
vector
opposit
direct
order
target
specif
cell
popul
brain
follow
adenovir
vectormedi
gene
transfer
transactiv
gene
place
control
cell
specif
promot
synapsin
glial
fibrillari
acid
protein
gfap
target
neuron
glial
cell
respect
follow
develop
next
gener
transactiv
new
teton
system
use
regul
express
follow
lentivir
vectormedi
gene
transfer
use
rtpcr
immunostain
author
abl
demonstr
tight
regul
express
transduc
area
brain
recent
regul
transgen
express
strategi
develop
express
tta
transactiv
tetoff
system
place
control
second
enhanc
system
base
transcript
activ
system
order
potenti
express
tta
protein
author
report
high
level
transactiv
product
increas
express
red
fluoresc
protein
dsred
rat
brain
blesch
colleagu
among
first
ever
demonstr
regul
express
neurotroph
factor
brain
diseas
model
use
tetoff
system
control
express
nerv
growth
factor
ngf
gfp
rat
model
alzheim
diseas
transfer
regul
express
cassett
perform
use
primari
fibroblast
transduc
retroviru
regul
express
observ
month
initi
studi
follow
modifi
experi
transfer
regul
express
cassett
done
use
lentiviru
vector
product
ngf
activ
state
therapeut
effect
cell
rescu
cholinerg
neuron
similar
anim
treat
vector
continu
express
ngf
recent
group
studi
effect
regul
bdnf
express
axon
growth
rat
model
spinal
cord
injuri
primari
fibroblast
transduc
retroviru
carri
teton
system
control
bdnf
gfp
express
implant
rat
immedi
follow
injuri
spinal
cord
regul
transgen
express
observ
month
follow
gene
transfer
product
bdnf
result
strong
axon
growth
lesion
site
rat
model
huntington
diseas
hd
striatal
inject
quinolo
acid
provok
patholog
chang
reminisc
hd
patholog
especi
degener
striatal
neuron
use
reguli
colleagu
studi
regul
neurotroph
factor
express
follow
lentivir
vectormedi
gene
transfer
cntf
control
tetoff
system
cntf
express
could
turn
administ
dox
via
drink
water
striatal
neuron
protect
degener
quinolo
acid
differ
strategi
develop
treatment
parkinson
diseas
use
regul
transgen
express
one
possibl
restor
regul
dopamin
product
inhibit
parkinson
diseas
striatum
tempor
overexpress
tyrosin
hydroxylas
th
rate
limit
enzym
dopamin
biosynthesi
second
strategi
would
express
neurotroph
factor
protect
dopaminerg
neuron
striatum
degener
diseas
exampl
neurotroph
factor
gdnf
shown
improv
phenotyp
parkinson
diseas
administ
long
time
follow
continu
express
brain
howev
continu
overexpress
gdnf
brain
lead
advers
effect
includ
downregul
tyrosin
hydroxylas
th
group
vogel
colleagu
use
lentivir
vector
transfer
express
cassett
contain
th
lu
control
teton
system
author
report
induc
transgen
express
two
order
magnitud
day
dox
administr
via
drink
water
dose
mgml
anoth
group
transplant
neuron
cell
line
stabli
transfect
tetoff
system
regul
product
th
striatum
rat
product
dopamin
partial
control
period
month
studi
order
attempt
regul
express
neurotroph
factor
express
gdnf
place
control
teton
system
employ
transactiv
two
vector
system
prove
feasibl
strategi
two
vector
one
encod
report
gene
gfp
second
encod
teton
system
initi
inject
ratio
striatum
dox
given
via
drink
water
mgml
week
gfp
express
cell
found
induc
anim
inject
two
vector
express
gdnf
control
teton
system
result
differ
gdnf
express
noninduc
induc
anim
background
level
elev
indic
rather
strong
leakag
system
dilut
vector
stock
result
lower
gdnf
level
induc
state
also
almost
undetect
gdnf
express
state
upon
withdraw
dox
drink
water
gdnf
protein
level
complet
reduc
within
week
th
protein
express
return
normal
within
week
indic
gdnfinduc
downregul
th
revers
event
use
tetrkrab
system
regul
gdnf
express
follow
lentivir
vectormedi
gene
transfer
studi
szulc
et
al
last
period
week
abl
turn
gdnf
express
differ
follow
dox
administr
via
drink
water
mgml
anoth
strategi
express
gdnf
develop
use
autoregulatori
loop
control
transgen
express
follow
inject
singl
aav
vector
initi
shown
express
gfp
could
induc
rat
brain
administr
dox
supplement
food
display
increas
mean
total
fluoresc
intens
introduct
gdnf
cdna
vector
inject
striatum
anim
continu
induc
mgml
dox
via
drink
water
gdnf
express
increas
induc
anim
remain
undistinguish
noninduc
anim
introduct
wpre
sequenc
behind
gdnf
gene
increas
protein
level
induc
state
wherea
basal
level
higher
biolog
activ
transgen
gdnf
proven
downregul
th
dopaminerg
termin
neuron
induc
anim
recent
differ
express
pattern
express
cassett
contain
teton
system
cmv
promot
drive
gfp
express
follow
aavmedi
gene
transfer
assess
group
found
differ
wide
use
strategi
treatment
cancer
constitut
express
suicid
gene
render
cancer
cell
suscept
specif
antitumour
drug
combin
kinas
gancyclovir
gcv
wide
use
system
cancer
gene
therapi
shown
immunotherapeut
approach
combin
cytotox
properti
kill
glioma
cell
presenc
gcv
alon
combin
immunostimulatori
effect
fmslike
tyrosin
kinas
ligand
effici
elimin
larg
intracrani
malign
glioblastoma
rat
howev
use
first
gener
adenovir
vector
detect
immun
respons
survivor
glioma
cancer
demonstr
need
regul
express
transgen
particularli
turn
case
success
therapeut
outcom
order
meet
challeng
strategi
develop
regul
express
mediat
combin
teton
strategi
vector
transfer
brain
parenchyma
high
capac
adenoviru
devoid
wild
type
adenovir
sequenc
therefor
less
immunogen
compar
previou
adenoviru
base
vector
system
initi
use
report
gene
express
control
combin
teton
system
ttskid
express
driven
either
human
hcmv
mous
mcmv
cytomegaloviru
earli
promot
element
within
day
dox
administr
via
drink
water
transgen
express
reach
maximum
decreas
background
level
within
day
withdraw
dox
observ
studi
express
induc
state
depend
dose
dox
administ
induc
transgen
express
best
background
level
lowest
mcmvteton
system
importantli
regul
transgen
express
possibl
even
presenc
strong
system
immun
reaction
adenovirus
highlight
possibl
use
system
patient
prior
exposur
adenoviru
common
human
infect
therefor
author
continu
work
murin
promot
construct
express
cassett
would
control
express
immunostimulatori
protein
use
hcad
vector
system
second
vector
encod
protein
toxic
presenc
gcv
driven
continu
promot
cytotox
activ
would
initi
applic
gcv
shown
tight
control
transgen
express
human
glioma
cell
system
studi
canin
glioma
cell
spontan
develop
glioblastoma
multiform
varieti
dog
breed
make
anim
preciou
larg
anim
model
develop
gene
therapi
strategi
diseas
hcad
success
transduc
dog
glioma
cell
exert
antitumour
effect
cell
vitro
therefor
strategi
may
possibl
treatment
option
glioblastoma
multiform
dog
subsequ
human
clinic
trial
interest
observ
made
group
immunis
mice
report
gene
transactiv
would
elicit
immun
respons
subsequ
loss
express
transduc
cell
brain
mice
chronic
constrict
injuri
cci
sciatic
nerv
rat
model
develop
antinocicept
therapi
neuropath
pain
diseas
patient
suffer
intract
pain
overproduct
brain
reduc
pain
sensit
cci
therefor
might
repres
potenti
therapi
patient
suffer
neuropath
pain
twoplasmid
gene
therapi
strategi
use
tetoff
system
regul
express
proopiomelanocortin
precursor
gene
develop
test
rat
model
cci
express
regul
durat
day
intraperiton
administr
dox
nocicept
sensit
reduc
rat
express
protein
attempt
develop
strategi
clinic
relev
set
author
produc
threeplasmid
strategi
code
proopiomelanocortin
gene
rtta
transactiv
tt
silenc
three
plasmid
coelectropor
spinal
cord
rat
analges
potenti
measur
heat
mechan
sensit
test
express
robust
upon
intraperiton
dox
administr
period
day
durat
experi
anoth
strategi
regul
express
transgen
brain
use
stabli
transfect
embryon
stem
cell
whose
progeni
cell
express
transgen
follow
transfer
certain
organ
gfp
express
stem
cell
express
control
teton
system
implant
brain
mice
express
effici
control
dox
administr
period
day
recent
teton
system
use
regul
express
sirna
block
express
integrinlink
kinas
ilk
follow
raavmedi
gene
transfer
nucleu
accumben
rat
condit
knockdown
ilk
express
construct
studi
function
kinas
normal
brain
structur
use
neuron
specif
promot
synapsin
gene
promot
drive
express
assur
highli
specif
neuron
transgen
express
within
two
week
dox
administr
mgkg
express
ilk
markedli
reduc
return
normal
valu
within
day
dox
withdraw
studi
show
condit
gene
silenc
establish
distinct
brain
region
use
raav
deliv
tetonregul
sirna
express
system
could
potenti
use
downregul
product
toxic
protein
brain
certain
cn
disord
possibl
regul
transgen
express
studi
sever
group
liver
rodent
primat
rodent
model
human
hematopoiesi
cancer
cartilag
tissu
one
strategi
treat
patient
hepat
c
system
administr
antivir
molecul
interferon
treatment
viral
infect
effect
rel
short
halflif
protein
circul
make
difficult
obtain
suffici
protein
level
liver
sustain
period
howev
express
liver
follow
viral
vectormedi
gene
transfer
may
constitut
effect
treatment
option
patient
hepat
c
mention
induc
gene
express
system
would
appropri
order
avoid
occurr
potenti
neg
side
effect
express
protein
time
teton
system
employ
control
express
hdtetifn
liver
mice
follow
adenovir
vectormedi
gene
transfer
day
dox
administr
via
drink
water
concentr
uml
observ
serum
hdtetifn
inject
mice
withdraw
dox
drink
water
result
rapid
decreas
serum
concentr
undetect
level
within
day
level
serum
induc
mice
depend
dose
dox
administ
final
author
test
effect
regul
express
surviv
rate
mice
challeng
lethal
dose
liver
toxic
coronaviru
express
result
prolong
surviv
anim
reduc
liver
damag
due
activ
express
antivir
gene
follow
encourag
result
author
aim
extrapol
system
mous
nonhuman
primat
monkey
genu
sanguinu
commonli
call
tamarin
propos
surrog
model
studi
viru
induc
hepat
infect
flaviviru
gb
viru
b
gbvb
studi
effect
express
follow
gene
transfer
liver
model
adenovir
vector
develop
control
express
tamarin
use
teton
system
follow
success
demonstr
function
system
mice
rat
vector
inject
intraven
monkey
initi
test
regul
express
liver
day
postinject
transgen
express
induc
day
oral
administr
dox
mgkg
two
monkey
exhibit
fold
increas
serum
level
two
monkey
show
lower
increas
serum
within
day
dox
withdraw
serum
level
decreas
baselin
level
induct
repeat
three
time
demonstr
reinduc
system
day
postinject
adenovir
vector
express
induc
dox
administr
anim
challeng
dose
gbvb
viru
moment
dox
given
continu
day
end
experi
ensur
local
liver
express
even
though
anim
becam
viraem
express
delay
significantli
onset
diseas
importantli
except
one
anim
exhibit
low
measur
level
secret
despit
inflamm
express
organ
author
discuss
variou
reason
lack
complet
protect
viral
hepat
compar
rodent
studi
includ
differ
maximum
level
serum
induc
mice
fold
compar
primat
maxim
often
observ
discrep
need
taken
account
develop
gene
therapi
strategi
mous
larg
anim
model
differ
mous
model
chronic
hepat
b
viru
infect
regul
express
control
teton
system
deliv
system
mice
two
adenovir
vector
liverspecif
transgen
express
assur
use
liveractiv
protein
promot
plap
author
report
low
basal
express
tight
regul
express
upon
dox
administr
via
drink
water
hemophilia
coagul
disord
caus
defect
blood
clot
factor
fix
product
order
treat
patient
diseas
regul
express
miss
factor
liver
would
provid
potenti
altern
repeat
administr
protein
prolong
express
without
regulatori
system
vigna
colleagu
report
regul
express
fix
liver
scid
mice
follow
system
administr
singl
lentivir
vector
contain
tetoff
system
regul
studi
mice
inject
differ
amount
lentivir
vector
regul
fix
express
upon
dox
administr
via
drink
water
observ
period
day
anoth
studi
employ
adenovir
vector
deliveri
teton
system
control
fix
express
upon
deliveri
vector
scid
mice
express
fix
could
regul
oral
administr
dox
via
drink
water
least
month
group
mizuguchi
colleagu
studi
regul
express
adenovir
vector
contain
seap
gene
control
combin
teton
system
mice
addit
regul
express
lacz
phospholipas
studi
mice
follow
adenovir
vector
inject
lung
lungtarget
gene
transfer
intraven
administr
livertarget
gene
transfer
respect
express
transgen
hematopoiet
precursor
cell
effici
transduc
ex
vivo
requir
integr
express
cassett
genom
system
could
potenti
appli
regul
express
certain
gene
defin
lineag
precursor
cell
hematopoiesi
vigna
colleagu
develop
lentiviru
vector
base
system
regul
express
gfp
lu
human
cord
blood
cell
engraft
subleth
irradi
nodscid
mice
tetsystem
employ
tetoff
system
kinet
ttamedi
control
transgen
express
similar
observ
studi
switch
system
dox
administ
via
drink
water
within
day
transgen
express
detect
switch
howev
took
week
complet
restor
transgen
express
anim
slow
clearanc
induc
drug
defin
kinet
system
second
group
develop
lentiviru
vector
seap
express
control
differ
version
pure
teton
combin
teton
system
base
observ
author
propos
simpl
teton
system
appropri
regulatori
system
control
transgen
express
hematopoiet
system
mention
chapter
wide
use
strategi
treat
cancer
introduc
suicid
gene
cancer
cell
thu
render
suscept
antitumour
drug
gcv
strategi
base
system
develop
treatment
human
breast
cancer
model
mice
initi
two
plasmid
first
contain
gene
control
induc
promot
second
contain
rtta
transactiv
gener
retrovir
vector
plasmid
two
vector
plasmid
cotransduc
human
breast
cancer
cell
day
follow
dox
induct
cell
implant
mice
sever
combin
immunodefici
scid
bear
breast
cancer
xenograft
follow
gcv
administr
tumour
cell
bear
produc
toxic
molecul
subsequ
erad
tissu
importantli
due
bystand
effect
known
effect
adjac
cell
implant
tumour
xenograft
also
arrest
growth
tumour
size
remark
decreas
follow
step
experi
perform
use
retrovir
vector
base
abovement
plasmid
transfer
regulatori
system
directli
tumour
xenograft
transplant
nude
mice
transduc
cell
sensit
gcv
begin
day
follow
retroviru
vector
administr
mrna
increas
significantli
tumour
tissu
within
week
tumour
size
decreas
remark
treat
mice
achiev
longterm
surviv
adjust
treatment
strategi
subsequ
use
clinic
tworetrovir
vector
system
replac
one
vector
strategi
use
viru
direct
inject
vector
result
gcv
sensit
within
tumour
day
follow
vector
gcv
administr
similar
result
concern
tumour
size
mrna
level
observ
compar
retrovir
vector
studi
author
conclud
regul
express
togeth
administr
gcv
may
use
method
treatment
breast
cancer
solid
tumour
anoth
anticanc
strategi
employ
tumour
specif
express
toxic
protein
cancer
cell
gu
colleagu
design
express
cassett
tta
transactiv
place
control
human
telomer
revers
transcriptas
htert
promot
control
express
cytotox
protein
bax
express
cassett
encapsid
adenovir
vector
inject
subcutan
xenograft
tumour
mice
tumour
growth
effici
suppress
period
day
durat
experi
adenovir
vector
carri
tetoff
combin
teton
regulatori
system
drive
faslgfp
express
tumour
cell
develop
rubinchik
et
al
gener
stabl
cell
line
express
sirna
certain
import
tumourassoci
protein
control
teton
system
third
anticanc
strategi
tet
regul
express
system
studi
vivo
czauderna
colleagu
develop
stabl
human
prostat
cancer
cell
contain
sirna
direct
subunit
phosphatidylinositol
kinas
modifi
teton
system
anoth
group
develop
stabl
human
colon
cancer
cell
line
express
receptor
prooncogen
protein
control
teton
system
third
group
develop
hela
cell
contain
stabli
integr
express
cassett
compos
teton
system
drive
sirna
express
human
pololik
kinas
cartilag
damag
follow
acut
injuri
degen
disord
joint
frequent
strategi
aim
regener
damag
cartilag
bone
tissu
investig
express
growth
factor
would
stimul
regener
cartilag
bone
tissu
potenti
treatment
method
order
control
express
transgen
joint
ueblack
colleagu
develop
express
cassett
report
gene
lacz
control
teton
system
transfect
chondrocyt
cell
implant
osteochondr
defect
knee
new
zealand
rabbit
follow
three
week
doxmedi
gene
express
lacz
protein
could
detect
well
integr
implant
differ
strategi
involv
use
mesenchym
stem
cell
transfect
express
cassett
contain
teton
system
regul
express
bone
morphogen
highli
potent
osteoinduct
protein
upon
transplant
cell
radii
osteopen
mice
express
could
well
detect
induc
anim
bone
format
regener
observ
durat
month
anoth
group
report
even
shortterm
induct
express
follow
intraarticular
inject
stem
cell
contain
tetoff
control
express
cassett
result
induct
bone
format
knee
tissu
immun
respons
teton
transactiv
observ
follow
gene
transfer
muscl
follow
gene
transfer
retina
nonhuman
primat
tetregulat
system
studi
sever
group
last
preclin
model
nonhuman
primat
follow
gene
transfer
muscl
retina
liver
contrast
observ
retina
regul
transgen
express
persist
year
without
appar
cellular
humor
immun
respons
muscl
direct
gene
transfer
exhibit
differenti
imag
rtta
use
regul
express
macaqu
epo
seap
skelet
muscl
follow
raav
adenovirusmedi
gene
transfer
larg
major
individu
develop
immun
respons
rtta
protein
moullier
et
al
unpublish
data
immun
respons
respons
rapid
loss
rttamedi
control
transgen
express
due
destruct
genet
modifi
cell
includ
reaction
humor
cellular
immun
respons
occur
even
upon
use
musclespecif
desmin
promot
instead
ubiquit
promot
drive
rtta
express
moullier
unpublish
data
gener
novel
rtta
variant
show
improv
sensit
dox
reduc
background
activ
hope
variant
would
less
immunogen
muscl
direct
gene
transfer
howev
use
variant
regul
transgen
express
muscl
immun
respons
transactiv
still
detect
moullier
et
al
unpublish
data
demonstr
epitop
identifi
rtta
result
vitro
lysi
rttaexpress
cell
cytotox
lymphocyt
mutat
analysi
domin
epitop
led
appear
subdomin
epitop
suggest
antirtta
immun
respons
could
prevent
select
engin
transactiv
intramuscularli
raavinject
nonhuman
primat
lymphomonocyt
infiltr
associ
myofibr
destruct
document
phenotyp
analysi
infiltr
cell
show
presenc
cell
presenc
infiltr
concomit
detect
circul
antibodi
rtta
protein
quantit
reduct
raav
copi
number
inject
site
addit
weak
secret
specif
rtta
protein
detect
aav
vector
inject
anim
use
vitro
activ
lymph
node
mononuclear
cell
lnmc
ad
vector
inject
anim
ex
vivo
fresh
peripher
blood
mononuclear
cell
pbmc
stimul
rtta
polypeptid
vitro
stimul
pbmc
inject
anim
could
also
specif
lyse
target
cell
express
rtta
peptid
reason
inject
anim
mount
immun
respons
rtta
transactiv
remain
unknown
fact
one
anim
inject
immun
respons
rtta
develop
neutralis
antibodi
raav
capsid
moullier
et
al
unpublish
data
indic
individu
immunocompet
nonself
peptid
may
possibl
develop
spontan
toler
particular
peptid
factor
involv
transgenespecif
immun
respons
like
numer
depend
mainli
vector
system
use
rout
administr
exampl
nake
plasmid
inject
chemic
formul
plasmid
dna
physic
method
inject
dna
dose
inject
affect
immun
respons
profil
regard
rout
raav
rad
administr
poor
diffus
vector
follow
intramuscular
inject
like
one
major
reason
develop
transgenespecif
immun
respons
contrari
abil
teton
system
establish
longterm
transgen
express
regul
demonstr
retina
nonhuman
primat
follow
subretin
inject
raav
vector
fact
antibodi
direct
transactiv
rtta
could
detect
eye
serum
nonhuman
primat
anim
display
persist
regul
epo
secret
year
fig
consist
fact
unlik
skelet
muscl
retina
like
immuneprivileg
site
tetregulat
system
use
varieti
version
embed
plasmid
raav
adenoviru
lentiviru
hsv
vector
explor
potenti
system
differ
organ
applic
experiment
studi
demonstr
feasibl
approach
advanc
small
anim
rodent
model
larg
anim
model
ie
nonhuman
primat
particular
case
muscl
retina
liver
direct
gene
transfer
use
raav
hcad
transfer
vector
import
inform
deriv
regul
transgen
express
studi
larg
anim
first
differ
level
transgen
express
induc
noninduc
state
smaller
nonhuman
primat
compar
observ
rodent
even
vitro
exampl
muscl
differ
fold
observ
mice
nonhuman
primat
differ
fold
second
immun
reaction
teton
transactiv
detect
nonhuman
primat
follow
gene
transfer
muscl
initi
studi
mice
reveal
immun
reaction
advanc
tetregulat
system
sever
mileston
need
achiev
concern
muscl
direct
gene
transfer
approach
problem
immun
reaction
transactiv
need
overcom
immin
step
brain
direct
gene
therapi
studi
extrapol
result
rat
model
larg
anim
model
order
evalu
clinic
relev
set
immun
statu
effici
tetregulat
system
may
soon
case
brain
cancer
studi
canin
model
glioblastoma
multiform
exist
regard
gene
transfer
retina
clinic
relev
diseas
model
evalu
use
vector
tetregulat
system
control
express
therapeut
transgen
